Press Releases
AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference
December 17, 2025
MASON, Ohio --(BUSINESS WIRE)--Dec. 17, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating...
AtriCure Announces the First Patients Treated with Novel Dual Energy Platform
December 11, 2025
New technology combines Pulsed Field Ablation (PFA) and Advanced Radiofrequency Ablation with AtriCure’s EnCompass ® clamp to reduce treatment time for surgical ablation patients MASON, Ohio --(BUSINESS WIRE)--Dec. 11, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical...
AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 18, 2025
MASON, Ohio --(BUSINESS WIRE)--Nov. 18, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating...
AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025
October 29, 2025
Worldwide revenue of $134.3 million – an increase of 15.8% year over year (15.1% constant currency) Net loss of $0.3 million – an improvement of $7.6 million year over year Adjusted EBITDA of $17.8 million – an increase of $9.9 million year over year Generated $30.1 million of cash in the third...
AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial
October 28, 2025
Trial will evaluate the safety and effectiveness of the AtriCure Isolator ® Synergy™ EnCompass ® clamp and AtriClip ® Left Atrial Appendage Exclusion System to reduce the occurrence of new-onset atrial fibrillation in cardiac surgery patients MASON, Ohio --(BUSINESS WIRE)--Oct....
AtriCure to Participate in Upcoming Investor Conferences
October 27, 2025
MASON, Ohio --(BUSINESS WIRE)--Oct. 27, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating...
AtriCure to Announce Third Quarter 2025 Financial Results
October 08, 2025
MASON, Ohio --(BUSINESS WIRE)--Oct. 8, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter...
AtriCure Announces the Launch of the cryoXT™ Device for Post-Operative Pain Management Following Amputation
September 09, 2025
New device expands AtriCure’s market opportunity in post-operative pain management while addressing a significant unmet clinical need MASON, Ohio --(BUSINESS WIRE)--Sep. 9, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation...
AtriCure to Participate in the 2025 Wells Fargo Healthcare Conference
August 20, 2025
MASON, Ohio --(BUSINESS WIRE)--Aug. 20, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating...
AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025
July 29, 2025
Worldwide revenue of $136.1 million – an increase of 17.1% year over year (16.5% constant currency) Net loss of $6.2 million – an improvement of $1.8 million year over year Adjusted EBITDA of $15.4 million – an increase of $7.6 million year over year Generated $17.9 million of cash in the quarter...